A phase II trial randomly assign patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations to receive pemetrex and carboplatin (PC) followed with or without gefitinib for 6 months, and found that DFS was significantly longer among those who received PC-gefitinib than those who received PC alone20. Here, EGFR is linked to non-small cell lung carcinoma.